Actively Recruiting
Observational Study on the Prevalence and Risk Factors of Patients With Hyperkalaemia in Brazil
Led by AstraZeneca · Updated on 2026-04-22
6215
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a descriptive, retrospective study involving patients from private cardiology, nephrology, and dialysis clinics in Brazil who participated in the National Hyperkalaemia Diagnosis Campaign. The study used anonymised data from the Hi Technologies Ltda. database. The objective was to estimate and characterise the prevalence of hyperkalaemia (HK), as well as to analyse the demographic profile, clinical characteristics, risk factors and treatment patterns associated with total blood potassium levels.
CONDITIONS
Official Title
Observational Study on the Prevalence and Risk Factors of Patients With Hyperkalaemia in Brazil
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants aged 18 years or older
- Heart failure diagnosis (any phenotype)
- Chronic kidney disease at any stage
- Diagnosis of diabetes mellitus
- Diagnosis of systemic arterial hypertension
You will not qualify if you...
- Advanced malignant neoplasm under palliative treatment
- Other advanced diseases with life expectancy less than one year
- Missing information on hyperkalaemia risk factors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Research Site
Curitiba, Brazil
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here